Skip to main content

Table 1 Detailed clinical and demographic characteristics of the study groups

From: Circulating miRNA expression in asthmatics is age-related and associated with clinical asthma parameters, respiratory function and systemic inflammation

  Asthma, n = 59 Control, n = 59 p-value
Women, n/N (%) 36/59 (61%) 41/59 (69.5%) ns
age years, mean ± SD 54.5 ± 16.8 52.8 ± 18.3 ns
atopy, n/N (%) 35/59 (59.3%) 24/59 (40.7%) 0.006
BMI, median (25–75%) 27.7 (23.9–30.9) 24.8 (22.2–28.4) 0.02
BMI > 25, n/N (%) 40/59 (67.8%) 27/59 (45.8%) 0.01
FEV1%pred. val., median (25–75%) 93.5 (82.9–105) 110.6 (101.7–113.9)  < 0.001
FEV1%/FVC, mean ± SD 69.6 ± 9.3 77.2 ± 8.8 0.001
R5Hz %pred. value, median (25–75%) 129.8 (97.1–159.4) 94.8 (84.6–110.7)  < 0.001
δR5–R20% pred., median (25–75%) 23.6 (10.7–43.7) 15.4 (8.5–23.1) 0.006
δR5–R20 > 20%, n/N (%) 36/58 (62.1%) 19/58 (32.8%) 0.001
FeNO ppb, median (25–75%) 21.5 (17.5–28) 20 (17–24.5) ns
FeNO > 25 ppb n/N (%) 23/57 (40.4%) 13/57 (22.8%) 0.04
Number of comorbidities, median (25–75%) 4 (2–7) 1 (0–3)  < 0.001
ACT, median (25–75%) 21 (18–25)
  1. Normally-distributed data are presented as mean ± standard deviation and analysed by Student’s t-test. Variables that were not normally distributed are presented as median and 25–75% percentile (in parentheses) and analysed by the Mann–Whitney test. The χ2 test was used for testing relationships between categorical variables. Bold text indicates a statistically significant p-value
  2. FeNO fractional exhaled nitric oxide, ACT asthma control test, FEV1% pred. forced expiratory volume in one second % of predicted value, FEV1%FVC forced expiratory volume in one second/forced vital capacity ratio, R5Hz% pred. resistance at 5 Hz, % of predicted value, δR5–20 Hz difference of resistance at 5 and 20 Hz, BMI body mass index